May 5th, 2026

The call reflected a generally positive tone: the company beat Q1 expectations, raised and narrowed full-year adjusted operating income and EPS guidance, demonstrated productivity-led cost improvements, and highlighted strong IKC clinical and savings performance. Material investments in technology and AI were emphasized as strategic drivers of future clinical and operational outperformance. Offsetting items included near-term pressure from higher G&A (driven by technology spend), an IKC operating loss, modest treatment declines versus prior year, ACA enrollment/mix uncertainty that could pressure revenue per treatment later in the year, and unchanged free cash flow guidance. On balance, the positive beats, guidance raise, and structural investments outweighed the near-term headwinds.

Company Guidance

Management raised and narrowed 2026 financial guidance after a strong Q1: adjusted operating income guidance is now $2.15–$2.25 billion (roughly $40M higher at the midpoint) and adjusted EPS guidance is $14.10–$15.20 per share; Q1 results included $482M of adjusted operating income (about $50M ahead of forecast), $2.87 adjusted EPS and $140M of free cash flow. They raised full‑year treatment volume growth to +25–50 bps (implying +50–75 bps in treatments per normalized day), after Q1 treatments were down ~20 bps YoY while treatments per normalized day rose ~40 bps; revenue per treatment grew ~4% YoY in Q1 (company expects 1–2% for the year), patient care cost per treatment was roughly flat to Q4, IKC posted a $19M operating loss and international OI was $30M, leverage was 3.34x EBITDA, Q1 debt expense was $145M (expected to run similar quarterly), and the prior ~$40M ACA headwind remains under review as enrollment trends look slightly favorable.